E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 Mg/Kg Alone or in Combination With High Dose Interferon-Α2b in Advanced Melanoma
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2258
Full Text
Open PDFAbstract
Available in full text
Date
November 12, 2018
Authors
Publisher
American Association for Cancer Research (AACR)